Recently, these findings were confirmed in a specific AD mice model, in which PCSK9 inhibition by a monoclonal antibody led to improved hippocampus-dependent memory performances, occurring through the downregulation of LRP1-mediated Aβ clearance [50]. Here, LRP1 is linked to Alzheimer disease.